A Folinic Acid Protocol for Autism Spectrum and Related Developmental Disorders
I expect the first copies of my book to be forthcoming in the next couple of months. Unfortunately, navigating the learning curve for proper editing, formatting, copyright registration, publishing, and printing is a prerequisite for that hard-copy version to reach even the Amazon marketplace.
In the meantime, I have become frustrated with the way Leucovorin is presently being prescribed and administered, and I feel compelled to report a better approach to achieving success.
So, simply, I am putting up an abridged version of Chapter 5 to get families and doctors pointed in the right direction:
“The Main Course – Leucovorin”
This is a form of Vitamin B9, given as Folinic Acid (generic) and prescribed as Leucovorin Calcium tablets. Having treated thousands of patients with this supplement for over a decade, I have observed that oral daily doses as low as 800 micrograms (0.8mg.) lead to impressive improvements in speech apraxia, delay, echolalia, scripting, and lack of interactive verbal abilities.
While it would be great to inform parents that, “If you would just administer 20 or 30 milligrams per day of folinic acid to Junior, you might have 3 or 4 rough months with increased lack of focus or disruption, but there’s a light at the end of that tunnel.”
In most cases, it’s just not true!
There is NO CORRECT DOSE of Leucovorin
Other protocols recommend dosages of the folinic acid based on age, weight, or other laboratory data. We consistently observe positive outcomes in behavior and communication by administering much smaller amounts. Patience and following directions will produce obvious functional improvements at each level of verbal skill.
By first addressing patients’ other medical needs, then adding Leucovorin (usually prepared from five milligram tablets), starting doses in the range of 1.25 mg. to 5 mg. are quite useful. Sometimes, Leucovorin may be the reason why focus and attention appear so much more problematic in other regimens that employ this vitamin as the sole intervention. Also, when administering higher doses of folinic acid, behaviors become difficult to control, and pharmaceuticals or extra supplements are then prescribed for the child to address subsequent overactivity.
I only prescribe a single dose in the morning, as is my advice with all other ‘activating’ supplements. That way, we have fewer problems with sleep, and we are not required to give so much extra nighttime medication.
Moreover, we frequently assist patients who have achieved very positive results at the initiation of leucovorin with starting doses in the 10+ mg. range, only to observe overactive and repetitive behaviors intensify after a couple of months.
This is a list of the types of reactions that have been noted in patients who are taking Leucovorin, and how the Clinic’s responses have improved tolerance and therefore outcome at each language level.
Problem: Even at the lowest dose (Less than 1 mg.) there is poor toleration.
Resolution: Check for gastrointestinal and metabolic stress and treat appropriately. To achieve tolerance, decrease the additional extra activating B vitamin compounds that patients often take. Some extra B12 helps, for example, but it could be too much and interfere with the work of increasing processing in the brain, and throughout the body.
Problem: First dose shows too much stimming, but tolerable.
Resolution: Lower dose or give every other day.
Problem: After an increase, too much stimming is observed.
Resolution: Obviously, consider going to the previous dose, but re-consider and evaluate gastrointestinal and metabolic status (test blood and/or stool) and re-treat as necessary.
Problem: Doing well on stable dose but increase in overactivity ‘lately’.
Resolution: In this case, and especially if an increase in repetitive behaviors-restricted interests (‘OCD’ short for obsessive compulsive symptoms) is observed, the patient is asked to reduce the dose of Leucovorin significantly for days to weeks. This vacation will produce an observable decrease in the frequency and severity of this overreaction and improve the ability to redirect. If there is no solace, this indicates another reason to retest as appropriate.
The effective dose of the leucovorin can vary widely. The daily portion will be in a range of ¼ of a 5mg. pill per day (1.25 mg.), up to perhaps a 30 mg. or more, depending weakly on factors such as age or weight. However, there are strong associations with tolerance due to gastrointestinal health and ongoing inflammation. The outcome measure is the emergence of desirable improvements in awareness and communication enabling disruptive behaviors to become less extreme.
A rarely appreciated point about this valuable Leucovorin Protocol is that, as the patient improves and grows up, the dose will hopefully be decreased and discontinued over time! Cancer survivors who have had ‘Leucovorin Rescue’ to get their bone marrow working again no longer need that vitamin to produce key blood components.
Medically, this is not a folic acid deficiency per se, and Leucovorin is not a lifelong requirement. When processing comes into the neurotypical range as evidenced by improved and sustained peer interactions, all supplements and medications need to be reevaluated and only continued as necessary.
As the children demonstrate their newfound independence and ability to interact with others, it is imperative that caretakers view their subsequent behaviors as immaturity, rather than a new set of diagnoses requiring another set of pharmaceutical products.
It is best to recognize that the goal of this regimen is improved processing as evidenced by improvement at each level of speech acquisition. By utilizing the Leucovorin Protocol judiciously and within a healthy environment, then the Applied Behavioral Analyst (ABA), Occupational Therapist (OT), Physical Therapist (PT), parents and family will agree that the affected individual is returning to a more neurotypical life.
Stay tuned for the Leucovorin Book, and thank you for reading!
![]()
©️ TheAutismDoctor
2026
